Zachary Shriver

Dr. Zachary Shriver received his B.A, in Chemistry from Amherst College, summa cum laude, and his Ph.D. from MIT in Applied Biosciences.  He has built on an academic training foundation in biochemistry, glycobiology, and structural biology with over 20 years of industry experience, including leadership in multiple aspects of drug development efforts. He is the scientific founder of two biotech companies, Visterra (sold to Otsuka Pharmaceuticals for ~$430 million) and Momenta (NASDAQ: MNTA) and is currently the Chief Scientific Officer at Visterra, heading Research and Pharmaceutical Sciences.  He has built and led scientific teams from scratch as well as established laboratory operations for biotech companies. Notably, he made significant contributions to solving the 2008 heparin crisis and has advised the FDA and United States Pharmacopeia on biologics-based medicines. His research has led to development of 10+ drug candidates, with six INDs and two approved products: enoxaparin sodium and Glatopa (glatiramer acetate). In addition, he is an author on 100+ scientific publications and 60+ patents.

Dr. Shriver is expert in identifying and managing critical manufacturing aspects of biotechnology businesses.  He has been involved in everything from working with partners/vendors to utilize their manufacturing capabilities to optimize product development for specific companies to guiding their scientific teams on potential ways to reduce program risk, reduce timelines, and better prepare for various regulatory submissions.